Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying specific stocks in the market. We monitor 13F filings and institutional buying patterns because large investors often have superior information and research capabilities. We provide ownership data, fund flow analysis, and institutional positioning for comprehensive coverage. Follow institutional money with our comprehensive ownership tracking and analysis tools for smarter investment decisions.
This analysis evaluates Biogen Inc.’s (NASDAQ: BIIB) recently announced definitive licensing agreement with TJ Biopharma for Greater China rights to experimental antibody felzartamab, a key late-stage asset in the firm’s immunology pipeline. The $850 million total potential deal unlocks full global
Biogen Inc. (BIIB) - Secures Exclusive Global Felzartamab Rights via Greater China Licensing Deal, Shares Rally - PEG Ratio
BIIB - Stock Analysis
3610 Comments
915 Likes
1
Kycion
Active Reader
2 hours ago
Great summary of current market conditions!
👍 190
Reply
2
Ariha
Engaged Reader
5 hours ago
If only I had spotted this sooner.
👍 280
Reply
3
Nica
Registered User
1 day ago
Read this twice, still acting like I get it.
👍 111
Reply
4
Barbarann
Experienced Member
1 day ago
Incredible work, where’s the autograph line? 🖊️
👍 182
Reply
5
Gissele
Influential Reader
2 days ago
Real-time US stock news flow and impact analysis to understand how current events affect your portfolio holdings. Our news aggregation system filters through thousands of sources to bring you the most relevant information quickly.
👍 60
Reply
© 2026 Market Analysis. All data is for informational purposes only.